HK1200334A1 - 使用免疫球蛋白和 -抑制劑的聯合療法 - Google Patents
使用免疫球蛋白和 -抑制劑的聯合療法Info
- Publication number
- HK1200334A1 HK1200334A1 HK15100811.0A HK15100811A HK1200334A1 HK 1200334 A1 HK1200334 A1 HK 1200334A1 HK 15100811 A HK15100811 A HK 15100811A HK 1200334 A1 HK1200334 A1 HK 1200334A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunoglobulin
- inhibitor
- combination therapy
- therapy
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161538832P | 2011-09-24 | 2011-09-24 | |
PCT/EP2012/068643 WO2013041677A1 (en) | 2011-09-24 | 2012-09-21 | Combination therapy using immunoglobulin and c1-inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200334A1 true HK1200334A1 (zh) | 2015-08-07 |
Family
ID=46881067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100811.0A HK1200334A1 (zh) | 2011-09-24 | 2015-01-23 | 使用免疫球蛋白和 -抑制劑的聯合療法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10471142B2 (zh) |
EP (1) | EP2758076B1 (zh) |
JP (1) | JP6190368B2 (zh) |
KR (1) | KR101956585B1 (zh) |
CN (1) | CN104010656B (zh) |
AU (1) | AU2012311483B2 (zh) |
CA (1) | CA2848510A1 (zh) |
DK (1) | DK2758076T3 (zh) |
ES (1) | ES2714999T3 (zh) |
HK (1) | HK1200334A1 (zh) |
WO (1) | WO2013041677A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2683397B1 (en) | 2011-03-09 | 2017-08-09 | CSL Behring GmbH | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
ES2609070T3 (es) * | 2013-02-28 | 2017-04-18 | Csl Behring Gmbh | Agente terapéutico para el embolismo de líquido amniótico |
KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
EP2968434B1 (en) | 2013-03-15 | 2017-06-28 | Shire Viropharma Incorporated | C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae). |
EP2994160B1 (en) * | 2013-05-06 | 2019-07-03 | Baxalta Incorporated | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
PL3071219T3 (pl) | 2013-11-22 | 2019-04-30 | Shire Viropharma Inc | Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1 |
EP3258911A1 (en) * | 2015-02-20 | 2017-12-27 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
US10532087B2 (en) | 2015-06-03 | 2020-01-14 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
WO2022251654A1 (en) * | 2021-05-28 | 2022-12-01 | West Virginia University Board of Governors on behalf of West Virginia University | Mitoneet ligands for use in protection from tissue ischemic reperfusion injury |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2009158A (en) * | 1934-08-01 | 1935-07-23 | Ophthalmological Foundation In | Ophthalmic ergograph |
DE3228502A1 (de) | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
DE4227762A1 (de) | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
US5827832A (en) * | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
AU6083899A (en) | 1999-09-16 | 2001-04-17 | Aventis Behring Gmbh | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
CN101897969B (zh) * | 2003-02-21 | 2014-04-02 | 健泰科生物技术公司 | 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
CA2632400C (en) | 2005-12-21 | 2016-06-07 | Pharming Intellectual Property Bv | Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
EP2233499A1 (en) * | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
EP3708581A3 (en) | 2009-05-27 | 2021-10-20 | Takeda Pharmaceutical Company Limited | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
-
2012
- 2012-09-21 EP EP12761739.7A patent/EP2758076B1/en active Active
- 2012-09-21 KR KR1020147010605A patent/KR101956585B1/ko active IP Right Grant
- 2012-09-21 CA CA2848510A patent/CA2848510A1/en active Pending
- 2012-09-21 US US14/346,478 patent/US10471142B2/en active Active
- 2012-09-21 DK DK12761739.7T patent/DK2758076T3/en active
- 2012-09-21 JP JP2014531244A patent/JP6190368B2/ja active Active
- 2012-09-21 ES ES12761739T patent/ES2714999T3/es active Active
- 2012-09-21 CN CN201280046349.8A patent/CN104010656B/zh active Active
- 2012-09-21 AU AU2012311483A patent/AU2012311483B2/en active Active
- 2012-09-21 WO PCT/EP2012/068643 patent/WO2013041677A1/en active Application Filing
-
2015
- 2015-01-23 HK HK15100811.0A patent/HK1200334A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DK2758076T3 (en) | 2019-04-01 |
CN104010656B (zh) | 2016-02-24 |
US20140234293A1 (en) | 2014-08-21 |
KR20140075753A (ko) | 2014-06-19 |
JP2014526541A (ja) | 2014-10-06 |
AU2012311483B2 (en) | 2016-03-10 |
CA2848510A1 (en) | 2013-03-28 |
WO2013041677A1 (en) | 2013-03-28 |
CN104010656A (zh) | 2014-08-27 |
EP2758076B1 (en) | 2018-12-12 |
KR101956585B1 (ko) | 2019-03-11 |
ES2714999T3 (es) | 2019-05-31 |
EP2758076A1 (en) | 2014-07-30 |
US10471142B2 (en) | 2019-11-12 |
JP6190368B2 (ja) | 2017-08-30 |
AU2012311483A1 (en) | 2013-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211475A1 (zh) | 聯合治療 | |
ZA201305897B (en) | Combination therapy | |
HK1200334A1 (zh) | 使用免疫球蛋白和 -抑制劑的聯合療法 | |
EP2739144A4 (en) | COMPOUNDS AND ITS THERAPEUTIC USE | |
HK1201454A1 (zh) | 治療劑及其用途 | |
ZA201400120B (en) | Combination therapy | |
HK1191034A1 (zh) | -羧烷基耳他汀類及其應用 | |
PL2489413T3 (pl) | Przyrząd terapeutyczny | |
GB201216649D0 (en) | Agents and methods | |
GB201217439D0 (en) | Combination therapy | |
HK1197178A1 (zh) | 組合 療法 | |
EP2688588A4 (en) | FAST AND LONG-TERM IMMUNOLOGICAL THERAPEUTIC | |
EP2701744A4 (en) | COMBINATION THERAPY | |
EP2750508A4 (en) | COMPOUNDS AND THERAPEUTIC METHODS | |
HK1210426A1 (zh) | 結合療法 | |
GB2476194B (en) | Cover and fixing | |
GB201102221D0 (en) | Inventions and therapy | |
GB201102216D0 (en) | Inventions and therapy | |
GB201102231D0 (en) | Inventions and therapy | |
GB201102238D0 (en) | Inventions and therapy | |
GB201102228D0 (en) | Inventions and therapy | |
GB201102227D0 (en) | Inventions and therapy | |
GB201102226D0 (en) | Inventions and therapy | |
GB201102208D0 (en) | Inventions and therapy | |
GB201102222D0 (en) | Inventions and therapy |